Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.
Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's ...
As mentioned, many typical household cleaning sprays and wipes aren’t sufficient to get rid of norovirus. According to the ...
One of the main proteins that contributes to Alzheimer's disease is called phospho-tau (p-tau). When p-tau gets too many ...
Mass General Brigham researchers found that hyperphosphorylated tau, the main component of pathological tangles in Alzheimer’s disease, may have serve to help protect the brain from infection ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...
Researchers hoped they had finally found a way to get gene therapies past the blood-brain barrier. Then the first patient ...
This webcast features: Cecile Toussaint, Director Bioprocess Development, VVector Bio. The separation of full and empty adeno-associated virus (AAV) particles is a critical challenge in scalable ...
Scientists from Japan have developed a new technique for assessing whether adeno-associated virus (AAV) capsids are full or empty of their therapeutic DNA payload. The team hopes the research will ...
This valuable work presents an interesting strategy to interfere with the HBV infectious cycle as it identifies two previously unexplored HBc-Ag binding pockets. The experimental data is compelling ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback